FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “NanoViricides, Inc. Surges After Licensing the Human Coronavirus Field for Drug Development and Commercialization from TheraCour Pharma, Inc.”
NanoViricides, Inc. (NYSE: NNVC) surged over 20% in premarket trading after the company announced that it has completed the process of licensing the human Coronavirus field for drug development and commercialization from TheraCour Pharma, Inc.
NanoViricides is currently working on taking its two COVID-19 lead drug candidates, namely, NV-CoV-2- and NV-CoV-2-R, into human clinical trials and believes that these broad-spectrum anti-coronavirus drugs will continue to be effective even as the virus continues to mutate.
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. We are developing clinical candidates for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Our other lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, the Company has several antiviral programs in various pre-clinical stages.
For more information, please visit: NanoViricides, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.